

*VANMA83.001APC



PATENT

8/12
1/21
9/30/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Communi, et al.) Group Art Unit 1644
Appl. No. : 09/077,173)
Filed : November 12, 1998)
For : HUMAN PYRIMIDINE)
RECEPTOR (as amended herein))
Examiner : Murphy, J.)

RECEIVED

SEP 20 2000

TECH CENTER 1600/2900

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

09/13/2000 AWONDAF1 00000058 09077173

01 FC:202
02 FC:203

78.00 OP
18.00 OP

Dear Sir:

In response to the Office Action, mailed from the US Patent and Trademark Office on April 5, 2000 (Paper No. 10), please amend the above-captioned patent application as follows: --

IN THE TITLE:

Please cancel the original title "RECEPTOR AND NUCLEIC ACID ENCODING SAID RECEPTOR" and substitute in its place --HUMAN PYRIMIDINE RECEPTOR--.

IN THE SPECIFICATION:

On page 1 of the specification prior to the first line, please insert --This is the U.S. National Phase under U.S.C. §371 of International Application PCT/BE96/00123, filed November 21, 1996.--

IN THE CLAIMS:

70. (Amended) An isolated receptor having at least a two-fold preference for pyrimidine nucleotides over purine nucleotides, wherein said receptor has an amino acid sequence having more than 60% homology with the amino acid sequence shown in SEQ ID NO:2, wherein in the presence of pyrimidine nucleotides, the receptor presents a functional response to lower concentrations of pyrimidine nucleotides than to purine nucleotides as well as an increased response to similar concentrations of pyrimidine nucleotides than to purine nucleotides.